or Try an Advanced Search...

    Technical Analysis for NGNE - Neurogene, Inc.

    Grade Last Price % Change Price Change
    F 15.33 -11.03% -1.90
    NGNE closed down 11.03 percent on Wednesday, November 20, 2024, on 2.73 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical NGNE trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other -11.03%
    Lower Bollinger Band Walk Weakness -11.03%
    Older End-of-Day Signals for NGNE ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 17 hours ago
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakdown about 19 hours ago
    Up 1% about 20 hours ago
    2x Volume Pace about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NGNE Chart by TradingView
    Basic chart:

    Profile

    Neurogene, Inc. Description

    The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Rare Diseases Gene Therapy Medical Genetics Genetic Engineering Central Nervous System Disorders Gene Delivery Molecular Genetics Neurological Diseases Transgene

    Is NGNE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Neurogene GAAP EPS of -$1.19 in-line
    Nov 18 Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
    Nov 18 How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
    Nov 18 Neurogene stock plunges 36% on NGN-401 study update
    Nov 18 Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
    Nov 15 Earnings Scheduled For November 15, 2024
    Nov 12 Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
    Nov 12 Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data
    Nov 11 Neurogene plummets 35% on gene therapy trial data for Rett syndrome
    Nov 11 Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
    See more NGNE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 74.49
    52 Week Low 12.49
    Average Volume 292,861
    200-Day Moving Average 38.89
    50-Day Moving Average 45.88
    20-Day Moving Average 46.54
    10-Day Moving Average 41.50
    Average True Range 6.83
    RSI (14) 26.47
    ADX 30.56
    +DI 22.02
    -DI 48.12
    Chandelier Exit (Long, 3 ATRs) 54.01
    Chandelier Exit (Short, 3 ATRs) 35.76
    Upper Bollinger Bands 79.64
    Lower Bollinger Band 13.44
    Percent B (%b) 0.03
    BandWidth 142.26
    MACD Line -6.57
    MACD Signal Line -1.33
    MACD Histogram -5.237
    Fundamentals Value
    Market Cap 196.59 Million
    Num Shares 12.8 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.59
    Resistance 3 (R3) 18.93 18.19 18.04
    Resistance 2 (R2) 18.19 17.36 18.02 17.86
    Resistance 1 (R1) 16.76 16.85 16.39 16.42 17.68
    Pivot Point 16.02 16.02 15.84 15.85 16.02
    Support 1 (S1) 14.59 15.19 14.22 14.25 12.98
    Support 2 (S2) 13.85 14.68 13.68 12.80
    Support 3 (S3) 12.42 13.85 12.62
    Support 4 (S4) 12.08